Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Iterum Therapeutics PLC (ITRM)

NASDAQ
Currency in USD
Disclaimer
1.430
-0.010(-0.69%)
Closed
After Hours
1.480+0.050(+3.497%)

ITRM Comments

any news
ITRM today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Friday, November 12, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
Should buy or not
I have !
Buy.
Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced a data presentation at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021.Title: In Vitro Antibacterial Susceptibility Testing of Sulopenem Against Category A and B Bio-threat Bacterial Pathogens
This study is not listed in their pipeline. But I suppose the news must be good.......
ITRM today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) during the third quarter of 2021 to discuss the steps required for potential resubmission of the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTI). In July, the Company announced that it had received a Complete Response Letter (CRL) from the FDA requesting additional data to support approval of oral sulopenem for the treatment of adult women with a uUTI. “We had a successful meeting with the FDA and have established various potential paths forward to address the request in the CRL for additional data in support of our NDA,” said Corey Fishman, Chief Executive Officer. “We are currently evaluating the optimal design for an additional Phase 3 uUTI study to be conducted prior to the potential resubmission of the NDA. We continue to believe in the ability of sulopenem to treat the growing problem of multi-drug resistant UTIs in the community.”. Iterum notes that cash, cash equivalents and short-term investments were $91.5 million at the end of the second quarter of 2021. Based on the current operating plan and subject to final determination of the design and planned conduct of additional clinical and potential nonclinical development for sulopenem, the Company believes that it is well positioned financially to fund its operations into the second half of 2023.
Iterum Therapeutics (ITRM): Q2 Non-GAAP EPS of -$0.04 beats by $0.02; GAAP EPS of $0.04 beats by $0.11.Cash, cash equivalents and short-term investments of $91.44M.Press Release“Despite...
Good news on the way
what good news?
Any one can analyse here plz
i can analyse ... how i can help you ? 🤭
"the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Friday, August 13, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business." - Before the open, this might be a good omen.
news source plz ?
ITERUm investor relations page
thanks bro
hold... and wait for the homerun pay day when it hits 2.50
cheap to buy
This has turned into a long term hold.
Long term investment, they will keep fighting for this FDA Approval
too bad
to be very honset I felt from the beginning with negative reply from FDA
wait till 25th of july
whats on july 25th?
FDA approval
rejected
Stock is a freaking DUD!
🔥🔥 lets goolooo
Short term garbage
xela was good, but they increased the capital.
This week ITRM will break $1.50. You’ll see
sure 0.7 level
its like 50% risk for short term
might have a good news, in the other hand its all negative reports!?
Big news next week 🔥🔥🚀
look at the financials, everything is in negative. no profits, no earnings filed, not even reported revenues. why anyone would buy this stock?
Although true you are oblivious to the potential and the stage ITRM already reached.
100 million in cash. are you omitting something?
Learn how to read in between the lines and not just earnings.
Most of gaps are closed
This will fall sharply
It hasn't been rejected!!! There is just a small issue with the product label. It will easily be addressed before July 25th.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.